RT Journal Article
SR Electronic
T1 The Incidence of Immune Mediated Inflammatory Diseases Following COVID-19: a Matched Cohort Study in UK Primary Care
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.06.22280775
DO 10.1101/2022.10.06.22280775
A1 Umer Syed
A1 Anuradhaa Subramanian
A1 David C Wraith
A1 Janet M Lord
A1 Kirsty McGee
A1 Krishna Ghokale
A1 Krishnarajah Nirantharakumar
A1 Shamil Haroon
YR 2022
UL http://medrxiv.org/content/early/2022/10/07/2022.10.06.22280775.abstract
AB Objective To assess whether there is an association between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection and the incidence of immune mediated inflammatory diseases (IMIDs).Design Matched cohort study.Setting Primary care electronic health record data from the Clinical Practice Research Datalink Aurum database.Participants The exposed cohort included 458,147 adults aged 18 years and older with a confirmed SARS CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR) or lateral flow antigen test, and no prior diagnosis of IMIDs. They were matched on age, sex, and general practice to 1,818,929 adults in the unexposed cohort with no diagnosis of confirmed or suspected SARS CoV-2 infection and no prior diagnosis of IMIDs.Main Outcome Measures The primary outcome measure was a composite of the incidence of any of the following IMIDs: 1. autoimmune thyroiditis, 2. coeliac disease, 3. inflammatory bowel disease (IBD), 4. myasthenia gravis, 5. pernicious anaemia, 6. psoriasis, 7. rheumatoid arthritis (RA), 8. Sjogren’s syndrome, 9. systemic lupus erythematosus (SLE), 10. type 1 diabetes mellitus (T1DM), and 11. vitiligo. The secondary outcomes were the incidence of each of these conditions separately. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for the primary and secondary outcomes comparing the exposed to the unexposed cohorts, and adjusting for age, sex, ethnic group, smoking status, body mass index, relevant infections, and medications.Results 537 patients (0.11%) in the exposed cohort developed an IMID during the follow-up period over 0.29 person years, giving a crude incidence rate of 3.54 per 1000 person years. This was compared 1723 patients (0.09%) over 0.29 person years in the unexposed cohort, with an incidence rate of 2.82 per 1000 person years. Patients in the exposed cohort had a 22% relative increased risk of developing an IMID, compared to the unexposed cohort (aHR 1.22, 95% CI 1.10 to 1.34). The incidence of three IMIDs were statistically significantly associated with SARS CoV-2 infection. These were T1DM (aHR 1.56, 95% CI 1.09 to 2.23), IBD (1.52, 1.23 to 1.88), and psoriasis (1.23, 1.05 to 1.42).Conclusions SARS CoV-2 was associated with an increased incidence of IMIDs including T1DM, IBD and psoriasis. Further research is needed to replicate these findings in other populations and to measure autoantibody profiles in cohorts of individuals with COVID-19, including Long COVID and matched controls.What is already known on this topicA subsection of the population who tested positive for SARS CoV-2 is suffering from post-Covid-19 condition or long COVID.Preliminary findings, such as case reports of post-COVID-19 IMIDs, increased autoantibodies in COVID-19 patients, and molecular mimicry of the SARS-CoV-2 virus have given rise to the theory that long COVID may be due in part to a deranged immune response.What this study addsCOVID-19 exposure was associated with a 22% relative increase in the risk of developing certain IMIDs, including type 1 diabetes mellitus, inflammatory bowel disease, and psoriasis.These findings provide further support to the hypothesis that a subgroup of Long Covid may be caused by immune mediated mechanisms.Competing Interest StatementSH reports receiving funding from NIHR and UKRI. US and AS report no competing interests. JL receives grant funding from NIHR, UKRI, Versus Arthritis, The Scar Free Foundation, FOREUM, Bayer Healthcare for which also she acts as a consultant.Funding StatementThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was reviewed and approved by the Clinical Practice Research Datalink (CPRD) Independent Scientific Advisory Committee (study #21_000712) on the 24th February 2022.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability statement: Access to anonymized patient data from CPRD is subject to a data sharing agreement containing detailed terms and conditions of use following protocol approval from the MHRA Independent Scientific Advisory Committee. Details about Independent Scientific Advisory Committee applications and data costs are available on the CPRD website (cprd.com).